ArticleBMC urology2015

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.

Takuya Koie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.